Clinical trial
IPI-926 Extension Protocol for Continuation of IPI-926 Treatment in Patients Experiencing Clinical Benefit While Enrolled in an IPI-926 Protocol
NCT01609179 is registered in ClinicalTrials.gov with Infinity Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- IPI-926 Extension Protocol for Continuation of IPI-926 Treatment in Patients Experiencing Clinical Benefit While Enrolled in an IPI-926 Protocol
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- March 31, 2012
- Completion date
- November 30, 2012
- Enrollment
- 9 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.